Summary
ABSTRACT Some of the most devastating neurodegenerative diseases such as multiple sclerosis, are characterized by chronic demyelination and a tissue environment that prevents efficient myelin repair and remyelination. While cell therapies have the potential to promote remyelination and restore lost neurological function, major barriers remain that hamper their successful translation to clinical treatment. Among these, survival of donor oligodendrocytes cell (OPC) preparations and maintenance of OPC fate are key obstacles. Notably, more than 95% of neural progenitor cells (NPCs) transplanted in
